Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers
Adam's Take By Adam Feuerstein Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst
Adam's Take By Adam Feuerstein TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin
Adam's Take By Adam Feuerstein Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug
Adam's Take By Adam Feuerstein Investor impatience with Gilead reclamation project sparks acquisition chatter
Adam's Take By Adam Feuerstein If biotech had a Mount Rushmore, whose heads would you chisel in the granite?
Adam's Take By Adam Feuerstein As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking
Adam's Take By Adam Feuerstein Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA
Adam's Take By Adam Feuerstein Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts
Biotech By Adam Feuerstein and Matthew Herper STAT’s guide to the most important, beneficial drugs approved in the past decade
Adam's Take By Adam Feuerstein Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list
Adam's Take By Adam Feuerstein And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!
Adam's Take By Adam Feuerstein Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!
Adam's Take By Adam Feuerstein The good, the bad, and the really, really ugly behind Sarepta’s drug approval
Adam's Take By Adam Feuerstein Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock
Adam's Take By Adam Feuerstein Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval
Adam's Take By Adam Feuerstein A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling
Adam's Take By Adam Feuerstein The bearish view of Acadia Pharma’s antipsychotic drug takes a hit with positive trial results
Adam's Take By Adam Feuerstein Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share
Adam's Take By Adam Feuerstein Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person
Adam's Take By Adam Feuerstein FDA’s Sarepta rejection is rooted in the past, and will weigh on its future
Adam's Take By Adam Feuerstein This troubled biotech needed cash, so it turned to a predatory lender: its own CEO
Adam's Take By Adam Feuerstein Sarepta’s bad week raised questions about its gene therapy program. Here are some answers
Adam's Take By Adam Feuerstein Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future
Adam's Take By Adam Feuerstein With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug
Adam's Take By Adam Feuerstein The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies
